TCM
IBRX icon

Tradewinds Capital Management’s ImmunityBio IBRX Stock Holding History

Tradewinds Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.38K Hold
500
– – ﹤0.01% 493
2026
Q1 		$3.83K Hold
500
– – ﹤0.01% 492
2025
Q4 		$990 Hold
500
– – ﹤0.01% 584
2025
Q3 		$1.23K Hold
500
– – ﹤0.01% 551
2025
Q2 		$1.32K Hold
500
– – ﹤0.01% 503
2025
Q1 		$1.5K Hold
500
– – ﹤0.01% 512
2024
Q4 		$1.28K Hold
500
– – ﹤0.01% 525
2024
Q3 		$1.86K Buy
+500
New +$2.31K ﹤0.01% 475

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Tradewinds Capital Management's IBRX Position: Q2 2026 in Review

Tradewinds Capital Management held its ImmunityBio (IBRX) position steady in Q2 2026 at 500 shares worth $4.38K. The position accounts for ﹤0.01% of the portfolio, ranked #493.

Tradewinds Capital Management first reported a position in IBRX in Q3 2024 and has held it in 8 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Tradewinds Capital Management held 500 shares of ImmunityBio worth $4.38K as of Q2 2026.
  • Tradewinds Capital Management left its ImmunityBio share count unchanged in Q2 2026.
  • ImmunityBio made up ﹤0.01% of Tradewinds Capital Management's portfolio in Q2 2026, its #493 holding.
  • Tradewinds Capital Management first reported a position in ImmunityBio in Q3 2024 and has held it in 8 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Tradewinds Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.